Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226765 · ClinicalTrials.gov registry record · Phase 3
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
A Phase 3 study of Obstructive Sleep Apnea, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT07226765 is a Phase 3 study of Obstructive Sleep Apnea that is actively recruiting participants, run by Amgen. The registered enrollment target is 250 participants, above the 220-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT07226765, a Phase 3 study of Obstructive Sleep Apnea, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are living with overweight or obesity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Maridebart cafraglutide
Study Locations (20)
Other
- Nemocnice Rudolfa a Stefanie Benesov as - Benesov U Prahy
- Cerebrovaskularni poradna sro - Ostrava - Poruba
- InnoDiab Forschung - Essen
- Diabeteszentrum Hamburg West - Hamburg
Florida
- Teradan Clinical Trials - Brandon
- Destiny Research Center - Palmetto Bay
- Clinical Research Center Of Florida - Pompano Beach
Texas
- FutureSearch Trials of Neurology - Austin
- Epic Medical Research - DeSoto - DeSoto
- Sleep Therapy & Research Center - San Antonio
Ontario
- Aggarwal and Associates Ltd - Brampton
- Wharton Medical Clinic - Hamilton
California
- Peninsula Research Associates - Rolling Hills Estates
New York
- Basil Clinical - Laurelton
North Carolina
- Monroe Biomedical Research - Monroe
Ohio
- CTI Clinical Research Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-11-25 |
| Est. Completion | 2028-09-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07226765
The ClinicalTrials.gov registry entry for NCT07226765 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 220-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (14% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obstructive Sleep Apnea appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07226765 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07226765 about?
NCT07226765 is a clinical study titled "Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy". This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are living with overweight or obesity.
What is the current status of trial NCT07226765?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2025-11-25. Estimated completion is 2028-09-13.
What conditions does trial NCT07226765 study?
This clinical trial studies the following conditions: Obstructive Sleep Apnea.
What interventions are being tested in trial NCT07226765?
The interventions under investigation include: Placebo (DRUG), Maridebart cafraglutide (DRUG).
Who is sponsoring clinical trial NCT07226765?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226765 being conducted?
This trial has 20 study locations across California, Florida, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obstructive Sleep Apnea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure
COMPLETED · Phase 3
-
PMP-300E (Smart Watch): Portable Monitoring Device Study
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.